- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Polyrizon enrolls first patient in U.S. allergy blocker trial | - | Investing.com | ||
| Di | Polyrizon Ltd.: Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker | 150 | GlobeNewswire (Europe) | First patient marks Polyrizon's transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker... ► Artikel lesen | |
| 04.09. | Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement | 3 | GlobeNewswire (USA) | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 04.09. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.09. | Polyrizon prices $4M registered direct offering | 1 | Seeking Alpha | ||
| 03.09. | Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement | 1 | GlobeNewswire (USA) | ||
| 02.09. | Polyrizon Tumbles on Clinical Studies | 1 | Baystreet.ca | ||
| 02.09. | Polyrizon Ltd.: Polyrizon Completes All Five U.S. Site Contracts for NASARIX First-in-Human Allergy Study | 2 | GlobeNewswire (USA) | ||
| 20.08. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.08. | Polyrizon completes contracting with all five clinical sites | 1 | Investing.com | ||
| 20.08. | Polyrizon Ltd.: Polyrizon Completes Clinical Site Network for NASARIX Study and Advances Toward Patient Enrollment | 1 | GlobeNewswire (USA) | ||
| 13.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.07. | Polyrizon Advances on Test Results | 1 | Baystreet.ca | ||
| 02.07. | Polyrizon: Positive Studiendaten zur Biokompatibilität beflügeln die Aktie | - | Investing.com Deutsch | ||
| 02.07. | Polyrizon completes biocompatibility tests for allergy nasal spray | 1 | Investing.com | ||
| 02.07. | Polyrizon Ltd.: Polyrizon Announces Successful Results for NASARIX Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial | 326 | GlobeNewswire (Europe) | Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 29.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.06. | Polyrizon erhält Zulassung für klinische Studie zu Allergen-Nasenspray | - | Investing.com Deutsch | ||
| 29.06. | Polyrizon Ltd.: Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial | 300 | GlobeNewswire (Europe) | Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 17.06. | Polyrizon receives U.S. patent publication notice for nasal drug delivery platform | 4 | Seeking Alpha |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,955 | +0,31 % | Heidelberg Materials schwächelt weiter, Qiagen zieht an: DAX-Ausblick | Der DAX bleibt im Konsolidierungsmodus. Nach einer zwischenzeitlichen Erholung geriet das größte deutsche Börsenbarometer am Freitag wieder unter Abgabedruck. Auf Wochensicht summierten sich die Abschläge... ► Artikel lesen | |
| VALNEVA | 2,685 | -0,26 % | Valneva-Aktie: Was die Daten zeigen, was Kleinanleger übersehen | ||
| NOVAVAX | 9,340 | +0,21 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,860 | -2,33 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| BIOXXMED | 1,080 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| OCUGEN | 0,913 | +1,90 % | Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa | Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP)... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,042 | -3,43 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,910 | +4,80 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,105 | -0,90 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,300 | -0,49 % | Jefferies bestätigt Kaufempfehlung für Sarepta Therapeutics wegen Pipeline-Potenzial | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,387 | -2,77 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,500 | 0,00 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 0,990 | -1,98 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference | Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,700 | +2,35 % | Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,275 (-2,55 %) liegt der Kurs bei 10,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.